Teva Pharmaceutical Industries Ltd (TEVA) is now in the Overvalued zone, suggesting that its current forward PE ratio of 11.97 is considered Overvalued compared with the five-year average of 4.80. The fair price of Teva Pharmaceutical Industries Ltd (TEVA) is between 14.21 to 23.11 according to relative valuation method. Compared to the current price of 33.86 USD , Teva Pharmaceutical Industries Ltd By Overvalued By 46.54%.

Relative Value

Fair Zone

14.21-23.11

Current Price：33.86

46.54%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Teva Pharmaceutical Industries Ltd (TEVA) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Teva Pharmaceutical Industries Ltd (TEVA) has a current Price-to-Book (P/B) ratio of 4.90. Compared to its 3-year average P/B ratio of 2.55, the current P/B ratio is approximately 92.07% higher. Relative to its 5-year average P/B ratio of 1.94, the current P/B ratio is about 152.98% higher. Teva Pharmaceutical Industries Ltd (TEVA) has a Forward Free Cash Flow (FCF) yield of approximately 1.63%. Compared to its 3-year average FCF yield of 5.86%, the current FCF yield is approximately -72.23% lower. Relative to its 5-year average FCF yield of 4.74%, the current FCF yield is about -65.64% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for TEVA competitors is 2.10, providing a benchmark for relative valuation. Teva Pharmaceutical Industries Ltd Corp (TEVA.N) exhibits a P/S ratio of 2.10, which is 0% above the industry average. Given its robust revenue growth of 12.61%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of TEVA increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of TEVA in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is TEVA currently overvalued or undervalued?

Teva Pharmaceutical Industries Ltd (TEVA) is now in the Overvalued zone, suggesting that its current forward PE ratio of 11.97 is considered Overvalued compared with the five-year average of 4.80. The fair price of Teva Pharmaceutical Industries Ltd (TEVA) is between 14.21 to 23.11 according to relative valuation method. Compared to the current price of 33.86 USD, Teva Pharmaceutical Industries Ltd is Overvalued By 46.54%.

What is Teva Pharmaceutical Industries Ltd (TEVA) fair value?

TEVA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Teva Pharmaceutical Industries Ltd (TEVA) is between 14.21 to 23.11 according to relative valuation method.

How does TEVA's valuation metrics compare to the industry average?

The average P/S ratio for TEVA's competitors is 2.10, providing a benchmark for relative valuation. Teva Pharmaceutical Industries Ltd Corp (TEVA) exhibits a P/S ratio of 2.10, which is 0.00% above the industry average. Given its robust revenue growth of 12.61%, this premium appears unsustainable.

What is the current P/B ratio for Teva Pharmaceutical Industries Ltd (TEVA) as of Mar 02 2026?

As of Mar 02 2026, Teva Pharmaceutical Industries Ltd (TEVA) has a P/B ratio of 4.90. This indicates that the market values TEVA at 4.90 times its book value.

What is the current FCF Yield for Teva Pharmaceutical Industries Ltd (TEVA) as of Mar 02 2026?

As of Mar 02 2026, Teva Pharmaceutical Industries Ltd (TEVA) has a FCF Yield of 1.63%. This means that for every dollar of Teva Pharmaceutical Industries Ltd's market capitalization, the company generates 1.63 cents in free cash flow.

What is the current Forward P/E ratio for Teva Pharmaceutical Industries Ltd (TEVA) as of Mar 02 2026?

As of Mar 02 2026, Teva Pharmaceutical Industries Ltd (TEVA) has a Forward P/E ratio of 11.97. This means the market is willing to pay $11.97 for every dollar of Teva Pharmaceutical Industries Ltd's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Teva Pharmaceutical Industries Ltd (TEVA) as of Mar 02 2026?

As of Mar 02 2026, Teva Pharmaceutical Industries Ltd (TEVA) has a Forward P/S ratio of 2.10. This means the market is valuing TEVA at $2.10 for every dollar of expected revenue over the next 12 months.

TEVA Valuation